Levetiracetam Gobens (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. By modulating SV2A activity, the drug stabilises neuronal firing and diminishes hyper‑excitability, which lowers the likelihood of seizure initiation and spread across the brain.

The specific dose of Levetiracetam Gobens is determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Healthcare professionals tailor the regimen to achieve optimal seizure control while minimising adverse effects.

Safety data for levetiracetam in pregnancy are limited, and the drug is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their physician, as levetiracetam does pass into breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers like carbamazepine or GABA‑enhancers such as valproate. It is generally well tolerated, has fewer drug‑enzyme interactions, and can be used as monotherapy or adjunctive therapy, making it a versatile option in epilepsy management.

Levetiracetam Gobens should be stored below 25 °C in a dry place. Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Levetiracetam Gobens is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include severe allergic reactions (rash, swelling, breathing difficulty), mood disturbances such as depression or suicidal thoughts, and rare blood disorders like leukopenia or thrombocytopenia. Patients should seek immediate medical attention if any of these symptoms develop.

Individuals with known hypersensitivity to levetiracetam or any of the tablet excipients should not use the product. Caution is also advised for patients with severe renal impairment, as dose adjustments are required, and for those with a history of psychiatric disorders.